TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00052936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 36Gy on BULK and extranodal involvement

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 36Gy on BULK and extranodal involvement

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 36Gy on BULK and extranodal involvement

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 36Gy on BULK and extranodal involvement
Study: NCT02386787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: an ultrasonography will be conducted before the anesthesic procedure to provide reliable quantitative information about the volume of gastric content.
Study: NCT04175340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BL-300-PFM04
Description: Preservative Free Lubricating and Rewetting Drops for use during contact lens wear

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OPTI-FREE
Description: Replenish Rewetting Drops
Study: NCT03732716

Intervention type: DIAGNOSTIC_TEST
Intervention: blood pressure measurement
Description: Intervention: Each patient's supine and standing blood pressure measurements will be recorded
Study: NCT01576120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bowel prep regimen first boost 6 oz. and second boost 3 oz.
Description: Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects administered a 6 oz. dose of Suprep as first boost and if needed addtional 3 oz. of Suprep (second boost)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bowel prep regimen first boost 3 oz. and second boost 6 oz.
Description: Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects administered a 3 oz. dose of Suprep as first boost and if needed addtional 6 oz. of Suprep (second boost)
Study: NCT03571425

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Protein
Description: A protein beverage will be consumed orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enteral Protein
Description: A protein beverage will be consumed via a naso-gastric feeding tube
Study: NCT03743714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga treatment; flexibility, balance and strength exercises.
Description: yoga treatment including flexibility exercises, balance exercises, and strength exercises.
Study: NCT01937013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Description: Oxytocin can be given intravenously (with a needle) or intranasally (a spray into the nose). The intravenous form of drug is approved by Health Canada for use in pregnancy. The intranasal formulation is not currently approved for use by Health Canada, but is used in Europe to induce labour in pregnant women or aid lactation (breastfeeding). Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nasal Mist
Description: Participants will be randomized to receive placebo on either study visit 2 or 3.
Study: NCT02533544

Intervention type: DRUG
Intervention: tenofovir disoproxil fumarate
Study: NCT00940290

Intervention type: OTHER
Group type: OTHER
Intervention: Graded Clinical Recommendation
Description: Graded recommendation in reference to a clinical condition written as it would be in a clinical practice guideline

Intervention type: OTHER
Group type: OTHER
Intervention: Graded Clinical Recommendation
Description: Graded recommendation in reference to a clinical condition written as it would be in a clinical practice guideline
Study: NCT01763112

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Group Galileo PAH
Description: The intervention/exercise group will do whole body vibration training on 4 days a week for 60 minutes over 4 weeks
Study: NCT05330624

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: plague vaccine(F1+rV)
Description: plague vaccine(F1+rV) (Lanzhou Institute of Biological Products Co.,Ltd) of 1.0ml, three doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: plague vaccine(F1+rV)
Description: plague vaccine(F1+rV) (Lanzhou Institute of Biological Products Co.,Ltd) of 1.0ml, three doses
Study: NCT01614795

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV
Study: NCT02008149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rowing exercise
Description: Individuals with SCI will use the rowing exerciser to see if there is a benefit to skeletal health in the lower limbs.
Study: NCT03674970

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine Film
Description: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.~The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Film
Description: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.~The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Film
Description: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.~The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
Study: NCT00143624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone maleate
Description: See Detailed Description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See detailed description.
Study: NCT02791035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration of Ipragliflozin
Study: NCT00631280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice
Description: Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a decision aid. Parent treatment preferences will be elicited and parents will receive coaching in deliberation about striking a balance between benefit and tolerable side effects. Parent will then choose the week that was best for their child and plan their next steps. Parents will also receive a consultation report that contains a physician dosage recommendation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recommendation
Description: Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a consultation report that also contains a physician dosage recommendation.
Study: NCT02244372

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cordyceps sinensis mycelium culture extract 0.76 g

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cordyceps sinensis mycelium culture extract 1.15 g

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01614795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03556449

Intervention type: DIAGNOSTIC_TEST
Intervention: High resolution ultrasound
Description: Using a high-frequency linear array transducer (18L6 HD)

Intervention type: DIAGNOSTIC_TEST
Intervention: High resolution ultrasound
Description: Using a high-frequency linear array transducer (18L6 HD)
Study: NCT01421407

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic ablation device
Description: High Intensity Focused Ultrasound treatment
Study: NCT03644849

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2RE® (Syneron Candela Corp, Wayland, MA)
Description: The intervention will include a single treatment of a lower extremity wound with ablative fractional carbon dioxide laser after MMS surgery.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham laser treatment
Description: A physician who is not blinded will perform a sham laser treatment on blinded subjects.
Study: NCT02058108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: Patients of any age and weight\< 30kg: telbivudine oral solution (20 mg/mL): 20 mg/kg up to 600 mg q.d corresponding to weight (kg) x1mL, p.o. once daily Patients \< 12 years old and weight≥ 30kg: telbivudine oral solution (20mg/mL), 600 mg/day corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: telbivudine film-coated tablet, 600 mg/day, corresponding to 1 tablet p.o. once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients of any age and weight \< 30kg: placebo oral solution corresponding to weight (kg) x1mL, p.o. once daily Patients \< 12 years old and weight ≥ 30kg: placebo oral solution corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: placebo tablet, corresponding to 1 tablet p.o. once daily
Study: NCT02315703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-Mosaic
Description: Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10\^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-Mosaic
Description: Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10\^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-Mosaic
Description: Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10\^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp140 DP Low-dose
Description: The gp140 DP vaccine containing 50 mcg of total protein, mixed with aluminum phosphate adjuvant (0.425 mg aluminum), per 0.5 mL injection administered intramuscularly.
Study: NCT04007770

Intervention type: OTHER
Group type: OTHER
Intervention: 16 week waiting period + optional Acupuncture
Description: Optional real acupuncture after 16 weeks waiting period. This arm is Closed to accrual.
Study: NCT00080938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide (TMZ) to be given at a dose of 75 mg/m2/day for 14 days, starting on D1 of whole brain radiotherapy (WBRT). Three weeks after completion of WBRT, TMZ will be given at a dose of 200 mg/m2/day x 5 days (or 150 mg/m2/day if prior chemotherapy) every 28-days,for an additional two cycles.
Study: NCT02930954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Patients received Gefitinib 250mg Qd orally until disease progression, intolerable toxicity or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Patients received Gefitinib 250mg Qd orally until disease progression, intolerable toxicity or death.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: Patients received Gefitinib 250mg Qd orally until disease progression, intolerable toxicity or death.
Study: NCT00941005

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electroacustimulation
Description: Electroacustimulation (EAS) is a derivative form of acupuncture therapy where a small current of electricity instead of a needle is used to stimulate an acupoint on the human body in an effort to create therapeutic effects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacustimulation
Description: Electroacustimulation (EAS) is a derivative form of acupuncture therapy where a small current of electricity instead of a needle is used to stimulate an acupoint on the human body in an effort to create therapeutic effects.
Study: NCT02315703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp140 DP Low-dose
Description: The gp140 DP vaccine containing 50 mcg of total protein, mixed with aluminum phosphate adjuvant (0.425 mg aluminum), per 0.5 mL injection administered intramuscularly.
Study: NCT01807975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forced oscillation
Study: NCT01742702

Intervention type: DRUG
Intervention: Nitroglycerin 0.25 mg (single dose, no longer given since January 2017)
Description: From the beginning of the study until the end of year 2016 a single dose of sublingual nitroglycerin was given to examine the associated acute haemodynamic effects (recordings completed).
Study: NCT00080938

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Standard whole brain radiation therapy 30 Gy in ten fractions.
Study: NCT02118090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine sulfate
Description: Chloroquine sulfate (NIVAQUINE) - 30 mg/kg for 3 days
Study: NCT02315703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp140 DP High-dose
Description: The gp140 DP vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp140 DP High-dose
Description: The gp140 DP vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp140 DP High-dose
Description: The gp140 DP vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline, 0.5 mL injection administered intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline, 0.5 mL injection administered intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline, 0.5 mL injection administered intramuscularly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline, 0.5 mL injection administered intramuscularly.
Study: NCT01614795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study: NCT01022385

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 24-hour low-residual diet
Study: NCT00089102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1,000 mg/m2/dose in 250 cc of NS IV over 30 minutes on Days 1 and 8 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: 100mg/m2/dose in 500 cc of D5W or NS IV over 90 minutes on days 1 and 8 of each 21 day cycle
Study: NCT03347006

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SPM Active
Description: Supplement or placebo will be administered orally between 9 am to 9:30 am.~* Each participant will give a baseline blood sample then they will be given one of the randomly allocated three doses of fish oil supplement, or a matching placebo in one of 8 study groups \[this will be on a 1:1:1:1:1:1:1:1 ratio\]. Blood will be collected again at 2h, 4h, 6h and 24h after supplementation/placebo, 12ml per time interval.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SPM Active
Description: Supplement or placebo will be administered orally between 9 am to 9:30 am.~* Each participant will give a baseline blood sample then they will be given one of the randomly allocated three doses of fish oil supplement, or a matching placebo in one of 8 study groups \[this will be on a 1:1:1:1:1:1:1:1 ratio\]. Blood will be collected again at 2h, 4h, 6h and 24h after supplementation/placebo, 12ml per time interval.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SPM Active
Description: Supplement or placebo will be administered orally between 9 am to 9:30 am.~* Each participant will give a baseline blood sample then they will be given one of the randomly allocated three doses of fish oil supplement, or a matching placebo in one of 8 study groups \[this will be on a 1:1:1:1:1:1:1:1 ratio\]. Blood will be collected again at 2h, 4h, 6h and 24h after supplementation/placebo, 12ml per time interval.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: SPM Active
Description: Supplement or placebo will be administered orally between 9 am to 9:30 am.~* Each participant will give a baseline blood sample then they will be given one of the randomly allocated three doses of fish oil supplement, or a matching placebo in one of 8 study groups \[this will be on a 1:1:1:1:1:1:1:1 ratio\]. Blood will be collected again at 2h, 4h, 6h and 24h after supplementation/placebo, 12ml per time interval.
Study: NCT03549429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical tapes: TegadermTM and EyeGard®
Description: TegadermTM and EyeGard® will be placed over patients' eyes during surgery with general anesthesia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical tapes: TegadermTM and EyeGard®
Description: TegadermTM and EyeGard® will be placed over patients' eyes during surgery with general anesthesia.
Study: NCT02118090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHA-PP
Description: DHA-PIP (Duo-Cotecxin®, DHA 40 mg and PP 320 mg, Zhejiang Holley Nanhu Pharamaceutical Co. Ltd, Jiaxing, Zhejiang province, China): one tablet of DHA-PIP contains 40 mg of dihydroartemisinin (DHA) and 320 mg piperaquine (PIP). It is an oral administration, one dose a day for 3 consecutive days. An adult dose (≥40 kg to 60kg body weight or more than 15 years old) consisted of three doses of 3 tablets over consecutive days (Total dose 9 tablets). The approximate total adult dose was 2-4 mg/kg for DHA and 20mg/kg for PP.
Study: NCT01653561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: The starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.
Study: NCT01742702

Intervention type: DRUG
Intervention: Nitroglycerin 0.25 mg (single dose, no longer given since January 2017)
Description: From the beginning of the study until the end of year 2016 a single dose of sublingual nitroglycerin was given to examine the associated acute haemodynamic effects (recordings completed).

Intervention type: DRUG
Intervention: Nitroglycerin 0.25 mg (single dose, no longer given since January 2017)
Description: From the beginning of the study until the end of year 2016 a single dose of sublingual nitroglycerin was given to examine the associated acute haemodynamic effects (recordings completed).

Intervention type: DRUG
Intervention: Salbutamol 400 µg (single dose, no longer given since January 2017)
Description: From the beginning of the study until the end of year 2016 a 400 µg dose of inhaled salbutamol was given to examine the associated acute haemodynamic effects (recordings completed).

Intervention type: DRUG
Intervention: Salbutamol 400 µg (single dose, no longer given since January 2017)
Description: From the beginning of the study until the end of year 2016 a 400 µg dose of inhaled salbutamol was given to examine the associated acute haemodynamic effects (recordings completed).

Intervention type: DRUG
Intervention: Salbutamol 400 µg (single dose, no longer given since January 2017)
Description: From the beginning of the study until the end of year 2016 a 400 µg dose of inhaled salbutamol was given to examine the associated acute haemodynamic effects (recordings completed).

Intervention type: DRUG
Intervention: Salbutamol 400 µg (single dose, no longer given since January 2017)
Description: From the beginning of the study until the end of year 2016 a 400 µg dose of inhaled salbutamol was given to examine the associated acute haemodynamic effects (recordings completed).

Intervention type: DRUG
Intervention: L-arginine (10 min infusion, no longer given since January 2017)
Description: From the beginning of the study until the end of year 2016 L-arginine infusion 10 mg/kg/min could be given for 10 minutes to examine acute haemodynamic effects (recordings completed).

Intervention type: DIETARY_SUPPLEMENT
Intervention: Liquorice (2 weeks, glycyrrhizin 290-370 mg daily, no longer given since 2012)
Description: Daily liquorice intake (daily glycyrrhizin dose 290-370 mg) for two weeks, measurements before and after intervention (recordings completed).

Intervention type: DIETARY_SUPPLEMENT
Intervention: Small milk casein-derived polypeptides (12 weeks daily, recordings completed 2011)
Description: Daily intake of yoghurt containing small milk casein-derived polypeptides (12 weeks) and placebo yoghurt (12 weeks), measurements before and after intervention (recordings completed 2011).

Intervention type: DRUG
Intervention: Bisoprolol (5 mg daily for 3 weeks, recordings completed 2011)
Description: Bisoprolol 5 mg daily for 3 weeks and placebo tablet daily for 3 weeks, double-blind, randomized, placebo-controlled cross-over protocol. Measurements before and after interventions (recordings completed 2011).
Study: NCT00810030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile solution of FERINJECT® in water for injection. In case of drip infusion FERINJECT® (10 to 20 ml) must be diluted only in sterile 0.9% sodium chloride (max 250 ml) FERINJECT® will be administered via i.v. drip infusion. Minimum administration time 15 minutes Dosage: 500 mg, 1000 mg, 1500 mg, according to patients' Hb and body weight